The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s ...

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven ...

Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...

Lumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children ...

Avadel Pharmaceuticals said its once-nightly narcolepsy drug Lumryz can now be used to treat children older than 7 years of ...

Biopharmaceutical company Avadel Pharmaceuticals plc (AVDL), Thursday announced that the U.S. Food and Drug Administration (FDA) has ...

Avadel Pharmaceuticals PLC (AVDL) reports significant revenue increase and anticipates positive operating income in the upcoming quarter.

To maintain its position in the narcolepsy market, the company now focuses on strategies such as defending its patents and pursuing legal action against competitors such as Avadel Pharmaceuticals ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Medscape Medical News, May 03, 2023 Alert FDA OKs Once-Nightly Sodium Oxybate for Narcolepsy Extended-release sodium oxybate (Lumryz) is taken once at bedtime for the treatment of cataplexy or ...